Table of Contents
Thrombosis
Volume 2012, Article ID 867121, 10 pages
http://dx.doi.org/10.1155/2012/867121
Review Article

Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions

1Serviço de Cardiologia, Hospital de Santa Cruz, Avenida Prof. Reinaldo dos Santos, 2790-134 Carnaxide, Portugal
2Serviço de Cardiologia, Hospital da Luz, Avenida Lusíada 100, 1500-650 Lisboa, Portugal
3CEDOC, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Rua da Junqueira 126, 1349-019 Lisboa, Portugal
4Serviço de Neurologia, Hospital Egas Moniz, 1349-019 Lisboa, Portugal
5Serviço de Medicina Interna, Hospital de São João, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
6Unidade de Saúde Familiar da Aguda, Avenida Padre Guilherme 21, 4405-010 Arcozelo, Portugal
7Hospital de Torres Vedras, Rua Dr. Ricardo Belo, 2560-324 Torres Vedras, Portugal

Received 15 December 2011; Revised 28 February 2012; Accepted 29 February 2012

Academic Editor: Edith Nutescu

Copyright © 2012 Jorge Ferreira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. U.S. Food and Drug Administration, “FDA approves Pradaxa to prevent stroke in people with atrial fibrillation,” 2010, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. View at Google Scholar
  3. European Medicines Agency, “Pradaxa’s approval for use in European Union,” 2011, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&mid=WC0b01ac058001d124. View at Google Scholar
  4. J. J. You, D. Singer, P. A. Howard et al., “Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, supplement 2, pp. e531S–e575S, 2012. View at Google Scholar
  5. J. Pink, S. Lane, M. Pirmohamed, and D. A. Hughes, “Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses,” British Medical Journal, vol. 343, Article ID d6333, pp. 1–14, 2011. View at Publisher · View at Google Scholar
  6. C. J. L. Murray and A. D. Lopez, “Mortality by cause for eight regions of the world: global burden of disease study,” The Lancet, vol. 349, no. 9061, pp. 1269–1276, 1997. View at Google Scholar · View at Scopus
  7. C. Sarti, D. Rastenyte, Z. Cepaitis, and J. Tuomilehto, “International trends in mortality from stroke, 1968 to 1994,” Stroke, vol. 31, no. 7, pp. 1588–1601, 2000. View at Google Scholar · View at Scopus
  8. D.-G. da Saude, “Risco de morrer em Portugal 2006—vol. 1 (In Portuguese),” Direcção-Geral da Saúde, Direcção de Serviços de Epidemiologia e Estatísticas de Saúde, Divisão de Epidemiologia, Lisboa, 2009, http://www.dgs.pt.
  9. M. Correia, M. R. Silva, I. Matos et al., “Prospective community-based study of stroke in Northern Portugal: incidence and case fatality in rural and urban populations,” Stroke, vol. 35, no. 9, pp. 2048–2053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Bonhorst, M. Mendes, P. Adragão et al., “Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: the FAMA study,” Revista Portuguesa de Cardiologia, vol. 29, no. 3, pp. 331–350, 2010. View at Google Scholar · View at Scopus
  11. L. Guize, F. Thomas, K. Bean, A. Benetos, and B. Pannier, “Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up,” Bulletin de l'Academie Nationale de Medecine, vol. 191, no. 4-5, pp. 791–805, 2007. View at Google Scholar · View at Scopus
  12. N. F. Murphy, C. R. Simpson, P. S. Jhund et al., “A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland,” Heart, vol. 93, no. 5, pp. 606–612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Deplanque, D. Leys, L. Parnetti et al., “Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management: main results of the SAFE II study,” British Journal of Clinical Pharmacology, vol. 57, no. 6, pp. 798–806, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Camm, P. Kirchhof, G. Y. Lip et al., “Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 31, pp. 2369–2429, 2010. View at Google Scholar
  15. European Medicines Agency, “Updates on safety of Pradaxa,” 2011, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/11/news_detail_001390.jsp&mid=WC0b01ac058004d5c1&jsenabled=true. View at Google Scholar
  16. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Google Scholar · View at Scopus
  17. European Medicines Agency. Pradaxa, “Summary of Product Characteristics,” 2011, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. View at Google Scholar
  18. L. Wallentin, S. Yusuf, M. D. Ezekowitz et al., “Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial,” The Lancet, vol. 376, no. 9745, pp. 975–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. A. Doggrell, “Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?” Drugs & Aging, vol. 27, no. 3, pp. 239–254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Noble and K. L. Goa, “Ticlopidine: a review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke,” Drugs & Aging, vol. 8, no. 3, pp. 214–232, 1996. View at Google Scholar · View at Scopus
  21. J. Aisenberg, S. J. Connolly, S. Yang et al., “Upper gastrointestinal symptoms occurring in dabigatran—treated subjects: an analysis of the RE-LY trial with 18,113 subjects,” in Proceedings of the American College of Gastroenterology Annual Scientific Meeting, Washington, DC, USA, October 2011.
  22. G. J. Hankey and J. W. Eikelboom, “Dabigatran etexilate: a new oral thrombin inhibitor,” Circulation, vol. 123, no. 13, pp. 1436–1450, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. V. Huisman, G. Y. H. Lip, H. C. Diener et al., “Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice,” Thrombosis and Haemostasis, vol. 107, no. 5, 2012. View at Google Scholar
  25. J. Stangier, H. Stähle, K. Rathgen, and R. Fuhr, “Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects,” Clinical Pharmacokinetics, vol. 47, no. 1, pp. 47–59, 2008. View at Google Scholar · View at Scopus
  26. Boehringer Ingelheim, “Pradaxa (dabigatran etexilate) Prescriber guide for stroke prevention in atrial fibrillation,” 2011, http://www.pradaxa.co.uk/downloads/spaf-prescriber-guide.pdf. View at Google Scholar
  27. C. E. DeRemer, J. S. Gujral, J. W. Thornton, and R. A. Sorrentino, “Dabigatran falsely elevates point of care international normalized ratio results,” The American Journal of Medicine, vol. 124, pp. e5–e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. van Ryn, T. Litzenburger, A. Waterman et al., “Dabigatran anticoagulant activity is safely neutralized by an antibody selective to dabigatran in vitro and in vivo models,” Journal of American College of Cardiology, vol. 57, no. 14, p. E-1130, 2011. View at Google Scholar
  29. I. Pragstl, B. Dörr, F. Kaspereit et al., “Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits,” Pathophysiology of Haemostasis and Thrombosis, vol. 37, pp. A94–P486, 2010. View at Google Scholar
  30. J. van Ryn, D. Ruhl, H. Priepke et al., “Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor, dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate,” Haematologica, vol. 93, supplement 1, p. 148, 2008, abstract 0370. View at Google Scholar
  31. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens et al., “Reversal pf rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, pp. 1573–1579, 2011. View at Google Scholar
  32. F. Wagner, H. Peters, S. Formella et al., “Effective elimination of dabigatran with haemodialysis: a phase-I single-centre study inpatients with end stage renal disease,” Circulation, vol. 124, no. 21, supplement, p. A13303, 2011. View at Google Scholar
  33. J. van Ryn, M. Neubauer, R. Flieg et al., “Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system (abstract P485),” Pathophysiology of Haemostasis and Thrombosis, vol. 57, p. A94, 2010. View at Google Scholar
  34. PHARMAC The Pharmaceutical Management Agency of New Zealand, “Guidelines for management of bleeding with dabigatran,” 2011, http://www.pharmac.govt.nz/2011/06/13/Dabigatran%20bleeding%20management.pdf. View at Google Scholar
  35. J. S. Healey, J. Eikelboom, J. Douketis et al., “Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin. Results from the RE-LY trial,” Circulation, vol. 124, no. 21, supplement, p. A12041, 2011. View at Google Scholar
  36. J. D. Douketis, A. C. Spyropoulos, F. A. Spencer et al., “Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, supplement 2, pp. e326S–e350S, 2012. View at Google Scholar
  37. L. Green and S. J. MacHin, “Managing anticoagulated patients during neuraxial anaesthesia,” British Journal of Haematology, vol. 149, no. 2, pp. 195–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Vandermeulen, “Is anticoagulation and central neural blockade a safe combination?” Current Opinion in Anaesthesiology, vol. 12, no. 5, pp. 539–543, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Horlocker, D. Wedel, J. Rowlingson et al., “American College of Chest Physicians. Executive summary: regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy. American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition),” Regional Anesthesia and Pain Medicine, vol. 35, pp. 64–101, 2010. View at Google Scholar
  40. N. Rosencher, M. P. Bonnet, and D. I. Sessler, “Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies,” Anaesthesia, vol. 62, no. 11, pp. 1154–1160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Stangier, K. Rathgen, H. Sthle, and D. Mazur, “Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study,” Clinical Pharmacokinetics, vol. 49, no. 4, pp. 259–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. L. Dans, S. Connolly, and M. Brueckmann, “Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial,” Presented at the European Society of Cardiology Congress, 2011, http://www.escardio.org/congresses/esc-2011/congress-reports/Pages/709-5-RE-LY.aspx.
  43. J. W. Eikelboom, L. Wallentin, S. J. Connolly et al., “Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial,” Circulation, vol. 123, no. 21, pp. 2363–2372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Prasugrel versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2001–2015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 361, no. 11, pp. 1045–1057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. S. Paikin, D. S. Wright, M. A. Crowther, S. R. Mehta, and J. W. Eikelboom, “Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents,” Circulation, vol. 121, no. 18, pp. 2067–2070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. Boehringer Ingelheim, RELY-ABLE Trial Emergency Information, 2011, http://www.rely-able-trial.com/Rely2Web/resources/jsp/emerency_sub_menu.jsp.
  48. F. van de Werf, J. Bax, A. Betriu et al., “Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology,” European Heart Journal, vol. 29, pp. 2909–2945, 2008. View at Google Scholar
  49. R. S. Wright, J. L. Anderson, C. D. Adams et al., “2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (Updating the 2007 Guideline): a report of the American College of cardiology foundation/American heart association task force on practice guidelines,” Circulation, vol. 123, no. 18, pp. 2022–2060, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. C. W. Hamm, J. P. Bassand, S. Agewall et al., “ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 32, pp. 2999–3054, 2011. View at Google Scholar
  51. S. J. Connolly, M. D. Ezekowitz, S. Yusuf, P. A. Reilly, and L. Wallentin, “Newly identified events in the RE-LY trial,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1875–1876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. H. Hohnloser, J. Oldgren, S. Yang et al., “Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY Trial,” Circulation, vol. 125, pp. 669–676, 2012. View at Google Scholar
  53. G. Y. H. Lip and D. A. Lane, “Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?” The American Journal of Medicine, vol. 123, no. 9, pp. 785–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Uchino and A. V. Hernandez, “Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials,” Archives of Internal Medicine, vol. 172, no. 5, pp. 397–402, 2012. View at Publisher · View at Google Scholar
  55. G. W. Barsness, J. S. Smith, B. I. Eriksson et al., “Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery,” Circulation, vol. 124, no. 21, supplement, p. A14413, 2011. View at Google Scholar
  56. J. Eikelboom, J. Oldgren, and P. Reilly, “No evidence of platelet activation in patients with atrial fibrillation who are treated with dabigatran: a substudy of the RELY Trial,” in Proceedings of the International Society on Thrombosis and Haemostasis, July 2011.
  57. R. A. Winkle, R. H. Mead, G. Engel et al., “The use of dabigatran immediately after atrial fibrillation ablation,” Journal of Cardiovascular Electrophysiology, vol. 23, no. 3, pp. 264–268, 2012. View at Publisher · View at Google Scholar
  58. ClinicalTrials.gov, “DAPPAR AF,” 2011, http://clinicaltrials.gov/ct2/show/NCT01468155?term=dappar&rank=1. View at Google Scholar
  59. R. Nagarakanti, M. D. Ezekowitz, J. Oldgren et al., “Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion,” Circulation, vol. 123, no. 2, pp. 131–136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. A. de Smedt, S. de Raedt, K. Nieboer, J. de Keyser, and R. Brouns, “Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran,” Cerebrovascular Diseases, vol. 30, no. 5, pp. 533–534, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. ClinicalTrials.gov, “IMS III,” 2006, http://clinicaltrials.gov/ct2/show/NCT00359424. View at Google Scholar
  62. H. C. Diener, S. J. Connolly, M. D. Ezekowitz et al., “Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial,” The Lancet Neurology, vol. 9, no. 12, pp. 1157–1163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. European Stroke Organization, Guidelines for Stroke Management, 2009, http://www.eso-stroke.org/recommendations.php?cid=9&sid=1.
  64. M. Watanabe, F. M. Siddiqui, and A. I. Qureshi, “Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment,” Neurocritical Care, vol. 16, no. 1, pp. 203–209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. W. Zhou, S. Schwarting, S. Illanes et al., “Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran,” Stroke, vol. 42, pp. 3594–3599, 2011. View at Google Scholar